Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL562372 | 1.00 | SOAT1 (0.38) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL561964 | 0.98 | SOAT1 (0.41) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL316931 | 0.98 | SOAT1 (0.41) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL154713 | 0.98 | SOAT1 (0.39) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL250912 | 0.95 | SOAT1 (0.42) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4151443 | 0.95 | SOAT1 (0.42) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL561987 | 0.93 | KDM4E (0.35) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL691540 | 0.93 | KDM4E (0.35) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31119920 | 0.91 | FAAH (0.39) | SOAT1TP53CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL232206 | 0.90 | KDM4E (0.36) | SOAT1TP53CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103585-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | Twinpig Biolab, Inc. (KR) | 2022-12-21 | — | — | EP | claimed |
| US-11484601-B2 | Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide | TWINPIGBIOLAB INC. (KR) | 2022-11-01 | — | — | US | claimed |
| US-20210244823-A1 | TARGETING M2-LIKE TUMOR-ASSOCIATED MACROPHAGES BY USING MELITTIN-BASED PROAPOPTOTIC PEPTIDE | TWINPIGBIOLAB INC. (KR) | 2021-08-12 | — | — | US | claimed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
| EP-0339080-B1 | IMPLANTATION OF PROSTHETIC DEVICES | CHIRON OPHTHALMICS INC. (US) | 1993-05-05 | — | — | EP | claimed |
| EP-0184710-A2 | Magnetic microspheres | BAYER AG (DE) | 1986-06-18 | — | — | EP | claimed |
| WO-2024130116-A2 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED TRANSFERRIN RECEPTOR‑BINDING MOLECULES | DENALI THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4362985-A1 | OLIGONUCLEOTIDE CONJUGATES TARGETED TO THE TRANSFERRIN RECEPTOR | Denali Therapeutics Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240141058-A1 | METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES | DENALI THERAPEUTICS INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-11912778-B2 | Methods of engineering transferrin receptor binding polypeptides | DENALI THERAPEUTICS INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024006976-A2 | TRANSFERRIN RECEPTOR BINDING MOLECULE CONJUGATES FOR DELIVERY OF OLIGONUCLEOTIDES TO CELLS | DENALI THERAPEUTICS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230406898-A1 | FUSION PROTEINS COMPRISING PROGRANULIN | DENALI THERAPEUTICS INC. (US) | 2023-12-21 | — | — | US | disclosed |
| EP-0339080-A4 | IMPLANTATION OF PROSTHETIC DEVICES. | CHIRON OPHTHALMICS INC (US) | 1989-11-07 | — | — | EP | disclosed |
| EP-0339080-A1 | IMPLANTATION OF PROSTHETIC DEVICES | CHIRON OPHTHALMICS INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| EP-0322146-A2 | Antibody and antigen | LYNXVALE LIMITED (GB) | 1989-06-28 | — | — | EP | disclosed |
| WO-1989004153-A1 | IMPLANTATION OF PROSTHETIC DEVICES | CHIRON OPHTHALMICS INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0175705-A1 | MACROPHAGE ACTIVATING FACTOR | CELLTECH LIMITED (GB) | 1986-04-02 | — | — | EP | disclosed |
| WO-1985003948-A1 | MACROPHAGE ACTIVATING FACTOR | CELLTECH LIMITED (GB) | 1985-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406898-A1 | FUSION PROTEINS COMPRISING PROGRANULIN | GRN, PRNP, GMFG | GLA 91/4885SOAT1 4542/4885TP53 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.